The Global Avascular Necrosis Market Size was valued at USD 692.4 Million in 2024 and is anticipated to reach USD 1,129.1 Million by 2033 with a CAGR of 5.7% from 2025 to 2033.

Avascular necrosis (AVN), also referred to as osteonecrosis, happens when the blood flow to bone tissue is blocked which leads to the condition getting worse over time. If blood cannot reach bones, oxygen and nutrients will be lacking and the cells will die. If the condition happens close to a joint, the bone structure can weaken and collapse as time goes on. Because of this collapse, the joint’s surface can be injured, leading to pain, limited use and eventually arthritis. The epiphysis of long bones, particularly the femoral head in the hip, is AVN’s preferred target, though knees, shoulders and other joints may also be involved. While fractures and dislocations can cause these, in many cases, the pain is not obvious and makes it harder to diagnose the problem early.

AVN can be caused by a range of issues that often happen together. Factors that may cause thrombosis are using corticosteroids for a long time, drinking too much alcohol, having blood clotting problems and having diseases such as lupus, sickle cell disease and Crohn’s disease. Both radiation therapy and Legg-Calve-Perthes disease in children can make them more likely to suffer from cancer. AVN can influence a single bone or several bones at once or it can develop in different bones at different times. While anyone can be affected, AVN most often influences adults in their 30s and 40s. Despite the ongoing damage to bones, the early stages of the disease often have no physical symptoms, so diagnosis is often put off.

Avascular Necrosis Market Dynamics

The increase in avascular necrosis which is commonly caused by long-term steroid use and drinking too much alcohol, is driving the market’s growth. The use of better medical imaging tools helps diagnose the condition earlier and more accurately. Raising awareness about why early detection and early treatment matter is helping the market grow.

The rise in osteoporosis and arthritis which are commonly related to avascular necrosis is also helping to fuel demand for new treatments and tests. As these diseases weaken bones, they increase the risk of AVN for people who are getting older around the world. Because bone-related disorders are more common in older people, the demand for better and easier-to-use treatment is increasing, mostly in areas where there are many elderly people. This is encouraging greater investment in healthcare infrastructure and innovation.

A major difficulty in treating avascular necrosis is that there are not many effective treatment options available. While medical research has advanced, no single treatment or cure for the condition has been found which can negatively affect patients’ outcomes. Most current treatments, like core decompression, bone grafting or joint replacement, help only some people and might not stop the condition from advancing in all patients. Since there is a lack of therapy options, it is difficult to treat this condition in different patient groups. In addition, the expensive treatment for avascular necrosis makes it harder for many to get care. Shoulder problems can be expensive because they involve scans, drugs, surgeries and often a long rehabilitation period. In places with underdeveloped healthcare systems and no or little insurance, these costs are often too high for patients. This situation leads to many people not being diagnosed or treated which can impact their lives and result in lasting disability.

Many emerging trends and innovations are creating significant growth opportunities for the AVN market. More people are choosing minimally invasive surgery because it saves time for recovery and reduces the risk of complications, making treatments more attractive and easy to access. With resorbable implants and bone graft substitutes, medical science is making bone regeneration easier and safer, giving rise to new product ideas. Using regenerative medicine, especially stem cell and gene treatments, may reverse damage to bones and return strength to joints, making a major difference in treating diseases. In addition, the trend toward personalized medicine means doctors can choose treatments that fit each person’s health situation and stage of disease. Coupled with the global rise in chronic conditions and an aging population both of which increase the risk of avascular necrosis, these factors are expected to drive demand for innovative, cost-effective solutions, positioning the market for sustained expansion.

Global Avascular Necrosis Market Segment Analysis

Avascular Necrosis Market By Disease Type

·       Traumatic Avascular Necrosis

·       Non-Traumatic Avascular Necrosis

As per the avascular necrosis industry analysis, the non-traumatic avascular necrosis market will account for a noteworthy portion of the market. Increased cases associated with metabolic bone disorders, excessive alcohol use, and other underlying medical conditions are the main causes of this growth. Particularly, non-traumatic avascular necrosis of the femoral head has become a major contributor to healthcare costs and a major cause of disability in younger people. The incidence of femoral head necrosis has also increased due to the increased use of drugs like testosterone and the ongoing prevalence of alcohol consumption, highlighting the critical need for early intervention and efficient treatment in this population.

Avascular Necrosis Market By Treatment Type

·       Drug Type

o   Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)

o   Osteoporosis Drugs

o   Cholesterol Lowing Drugs

o   Blood Thinners

o   Others

·       Therapy

o   Physical Therapy

o   Exercises

o   Gene Therapy and Surgery

In 2024, the drug type segment dominated the avascular necrosis (AVN) market. This dominance is primarily due to the extensive use of nonsteroidal anti-inflammatory medicines (NSAIDs) and osteoporosis medications to treat early-stage symptoms and halt disease development. These drugs are often used as the first line of treatment since they are more accessible, less expensive than surgical treatments, and can give pain relief and increase mobility. Furthermore, rising physician preference for pharmaceutical therapies in non-advanced illnesses has increased demand. While therapies like as gene therapy and surgery are gaining popularity, particularly in severe or advanced stages, their high cost and restricted availability have put drug-based treatments at the forefront of the market in 2024.

Avascular Necrosis Market By Route of Administration

·       Oral

·       Parenteral

In the market for avascular necrosis (AVN), the oral segment is anticipated to develop rapidly due to the growing use of anticoagulants, cholesterol-lowering medications, bisphosphonates, and nonsteroidal anti-inflammatory medicines (NSAIDs) for early-stage treatment. Compared to parenteral treatments, oral drugs have a number of benefits, such as increased patient compliance, reduced overall costs, and better convenience. This trend is further supported by the increasing demand for non-invasive treatments as well as ongoing advancements in oral medication formulations that improve therapeutic efficacy and bioavailability. Oral treatments continue to be the recommended method for controlling symptoms and delaying the advancement of the disease, which strengthens their strong position in the market as the number of AVN patients rises as a result of factors like long-term steroid usage and bad lifestyle choices.

Avascular Necrosis Market By Diagnosis

·       MRI

·       CT Scan

·       Biopsy

·       PET and X-ray

The avascular necrosis market forecast states that by 2033, the CT scan sub-segment would dominate the avascular necrosis market, primarily because of its sophisticated imaging capabilities that allow for accurate and timely diagnosis. CT scans, as opposed to conventional X-rays, provide fine-grained cross-sectional views of bone structures, making it easier to see AVN alterations in their early stages. This benefit greatly improves diagnostic precision and helps guide prompt treatment choices. The February 2024 debut of Royal Philips' CT 5300 system, which incorporates cutting-edge AI integration, is a noteworthy milestone that supports this trend. This technology, which is intended for diagnostic imaging, interventional treatments, and screening, improves diagnostic confidence, streamlines workflow, and guarantees increased system reliability, all of which eventually lead to better patient outcomes and increased productivity in clinical settings.

Avascular Necrosis Market By Sales Channel

·       Hospital Pharmacies

·       Retail Pharmacies

·       Online Pharmacies

Hospital pharmacy was one of the leading sales channels for avascular necrosis (AVN) in 2024. The main reason for this dominance is the large number of prescriptions written in hospital settings, where AVN is frequently identified and treated, especially in moderate to severe instances. Since hospitals are usually the initial place of care, patients might get prescribed drugs like NSAIDs, bisphosphonates, and anticoagulants right away. Furthermore, complicated AVN cases sometimes call for coordinated care that includes specialist consultations, surgical planning, and diagnostic imaging all of which are centered in hospital settings. Hospital pharmacies maintain their substantial market share by being a preferred channel for both doctors and patients thanks to this integrated approach, which also improves patient convenience and confidence.

Avascular Necrosis Market Regional Analysis

North America is currently the largest market for the treatment of avascular necrosis (AVN), thanks to a strong healthcare system, sophisticated diagnostic tools, and high patient awareness. Demand for both surgical and non-surgical treatment alternatives is being driven by the rise in AVN cases in the United States due to the rising prevalence of obesity, diabetes, and alcohol-related illnesses. Leading pharmaceutical and medical device businesses are also well-represented in the area, actively creating cutting-edge treatments that support market expansion.

Europe is right behind, with nations like France, Germany, and the United Kingdom leading the way in implementing innovative treatment modalities. The region's well-established healthcare systems, growing use of minimally invasive surgical methods, and government programs that support bone health all play a big role in the market's growth.

With a projected CAGR of about 7% over the course of the forecast period, the Asia-Pacific region is expected to experience the fastest growth rate in the AVN market. Rising healthcare costs, an expanding patient base, and increased knowledge of bone-related conditions in important countries like China, India, and Japan are the main causes of this increase. The accessibility and quality of AVN diagnosis and treatment are anticipated to significantly increase as these nations continue to invest in medical infrastructure and adopt cutting-edge technology, which will further propel regional market expansion.

Avascular Necrosis Market Leading Companies

The Avascular Necrosis players profiled in the report is Alkem Labs, Bayer AG, Dwarkesh Pharmaceuticals Private Limited, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., GSK, Pfizer, Inc., Novartis AG, Rochem International, Inc., and Solara Active Pharma Sciences Limited.

Avascular Necrosis Market Regions